| P50 | author | Moses Elisaf | Q56966508 |
| | Dimitri P Mikhailidis | Q62561943 |
| P2093 | author name string | Stavroula Tsiara | |
| | I. Anita Jagroop | |
| P2860 | cites work | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 |
| | Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort | Q24683880 |
| | Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets | Q28182270 |
| | Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease | Q28185314 |
| | Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 |
| | Selective serotonin reuptake inhibitors and myocardial infarction | Q28190260 |
| | In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease | Q28192888 |
| | Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by nitroprusside | Q28193055 |
| | The thienopyridines | Q28193168 |
| | Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 |
| | Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients | Q28194452 |
| | Value of thromboelastography in the assessment of platelet function | Q28196481 |
| | Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity | Q28364491 |
| | Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 |
| | Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 |
| | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 |
| | Platelet aggregation induced by ADP or epinephrine is enhanced in habitual smokers | Q30647300 |
| | Gamma glutamyl transferase | Q31010652 |
| | C-reactive protein as a marker for active coronary artery disease in patients with chest pain in the emergency room. | Q31113902 |
| | Mean platelet volume: the need for a reference method | Q71379629 |
| | Kinetics and distribution of platelets in man | Q71414967 |
| | Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis | Q71625829 |
| | Platelets and atherosclerosis | Q71629682 |
| | Platelet radiolabelling with 111 Indium for in vivo studies: a methodological reappraisal | Q71937401 |
| | Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets | Q72455808 |
| | Gamma-glutamyltransferase and vascular disease | Q73036132 |
| | Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl | Q73074808 |
| | Effects of antihypertensive treatment on platelet function in essential hypertension | Q73330198 |
| | Correlation between cholesterol, soluble P-selectin, and D-dimer in obese children and adolescents | Q73333612 |
| | Association between platelet glycoprotein Ibalpha genotype and ischemic cerebrovascular disease | Q73406282 |
| | Influence of platelet count and activity on thromboelastography parameters | Q73634920 |
| | The use of citrated whole blood in thromboelastography | Q73712553 |
| | Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter Thrombocytometer | Q73757377 |
| | Platelets | Q73761178 |
| | Thrombopoietin and mean platelet volume in coronary artery disease | Q73860177 |
| | Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy | Q74156255 |
| | Blood platelet activation evaluated by flow cytometry: optimised methods for clinical studies | Q74156338 |
| | Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention | Q74179999 |
| | Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests | Q74465760 |
| | PFA-100 system: a new method for assessment of platelet dysfunction | Q74525732 |
| | Reactivity of human platelets with immobilized fibrinogen is dictated by the chemical character of the surface | Q74587116 |
| | Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction | Q74611574 |
| | Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men | Q77136484 |
| | Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure | Q77423833 |
| | Correlation between serum gamma-glutamyl transferase activity and the platelet count | Q79773833 |
| | Value of Antiplatelet Therapy in Preventing Thrombotic Events in Generalized Vascular Disease | Q94558111 |
| | Are we mortgaging the medical profession? | Q95814757 |
| | Laboratory markers of platelet activation and their clinical significance | Q33329894 |
| | Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders | Q33332188 |
| | Evaluation of platelet function by flow cytometry | Q33332950 |
| | Platelet kinetics with indium-111 platelets: comparison with chromium-51 platelets | Q33477315 |
| | Platelets, aspirin, and cardiovascular disease | Q33598560 |
| | Physical activity in the prevention and treatment of a thrombogenic profile in the obese: current evidence and research issues | Q33792148 |
| | The evolving role of statins in the management of atherosclerosis | Q33818141 |
| | Platelet tests in the prediction of myocardial infarction and ischaemic stroke: evidence from the Caerphilly Prospective Study | Q33948808 |
| | Beneficial effect of moderate alcohol consumption on vascular disease: myth or reality? | Q33986482 |
| | Clopidogrel: a review of its use in the prevention of atherothrombosis | Q34030132 |
| | Homocysteine, coagulation, platelet function, and thrombosis | Q34049294 |
| | Diabetes and atherosclerosis: epidemiology, pathophysiology, and management | Q34646074 |
| | Blood platelet count and function are related to total and cardiovascular death in apparently healthy men | Q34792421 |
| | Effect of ethanol on vascular prostacyclin (prostaglandin I2) synthesis, platelet aggregation, and platelet thromboxane release | Q34996593 |
| | Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study | Q35009072 |
| | Platelets and lipoprotein (a): a brief overview of their role in the pathogenesis of atherothrombosis | Q36519500 |
| | Platelet function and lipid-lowering interventions | Q36519504 |
| | The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 |
| | Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease | Q37196898 |
| | Plasma albumin and platelet function: relevance to atherogenesis and thrombosis | Q37806205 |
| | Platelet adhesion | Q37947669 |
| | Doxazosin modifies serotonin-mediated rabbit urinary bladder contraction. Potential clinical relevance | Q39429360 |
| | Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo | Q40099233 |
| | Radiolabeling of platelets | Q40212348 |
| | Role of thrombosis in atherosclerosis and its complications | Q40597995 |
| | D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease | Q40639748 |
| | Soluble P-selectin and the risk of future cardiovascular events | Q40729226 |
| | Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque | Q40738771 |
| | One year after CAPRIE, IST and ESPS 2. Any changes in concepts? | Q40840335 |
| | Platelet hyperreactivity and prognosis in survivors of myocardial infarction | Q41229453 |
| | Molecular mechanisms of platelet adhesion and activation | Q41391442 |
| | Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. | Q41452120 |
| | Platelet Survival and Platelet Production in Acute Myocardial Infarction | Q41659641 |
| | Evaluation of circulating platelet-leukocyte conjugates: a sensitive flow cytometric assay well suited for clinical studies | Q42491840 |
| | Platelet glycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: The Framingham Heart Study | Q43669462 |
| | Influence of platelet size on outcome after myocardial infarction | Q43705998 |
| | Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction | Q43754686 |
| | Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity | Q43852839 |
| | Platelet and megakaryocyte changes in cholesterol-induced experimental atherosclerosis | Q43923970 |
| | The in vivo antithrombotic effect of wine consumption on human blood platelets and hemostatic factors | Q44035331 |
| | Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Témoins de l'Infarctus du Myocarde (ECTIM). | Q44039840 |
| | Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). | Q44053700 |
| | Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease | Q44083621 |
| | Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release | Q44167942 |
| | Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events | Q44216708 |
| | Increased platelet aggregation and activation in peripheral arterial disease | Q44276794 |
| | Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction | Q45282013 |
| | Blood platelet kinetics in normal subjects modelled by compartmental analysis | Q46765676 |
| | Platelet number and volume during myocardial infarction in relation to infarct size. | Q47214089 |
| | Fractionation of platelets according to size: functional and biochemical characteristics | Q47216141 |
| | Evidence that platelet buoyant density, but not size, correlates with platelet age in man | Q47286674 |
| | Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain | Q47293759 |
| | Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction | Q49031698 |
| | A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus. | Q50882314 |
| | Mean platelet volume as an indicator of platelet activation: methodological issues. | Q51541198 |
| | Comparison of three platelet markers for measurement of platelet survival time in healthy volunteers. | Q52642461 |
| | The clinical impact of platelet function testing. | Q53019290 |
| | Antithrombotic Secondary Prevention After Stroke. | Q53311507 |
| | Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. | Q54037459 |
| | Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease | Q58959199 |
| | Whole blood impedance platelet aggregometry and ischemic heart disease. The Caerphilly Collaborative Heart Disease Study | Q60687362 |
| | Diurnal variation in platelet aggregation with the PFA–100 platelet function analyser | Q61651166 |
| | Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter Thrombocytometer | Q61831047 |
| | Association Between P-Selectin Gene Polymorphisms and Soluble P-Selectin Levels and Their Relation to Coronary Artery Disease | Q61849180 |
| | Daily variations in platelet aggregation and adhesion in healthy subjects | Q68080998 |
| | Splenic platelet kinetics and platelet production after major reconstructive vascular surgery | Q68280985 |
| | Platelet activation in unstable coronary disease | Q68903080 |
| | In vitro and in vivo behavior of 111In-labelled platelets: an experimental study of healthy male volunteers | Q69397562 |
| | Platelet function in patients admitted with a diagnosis of myocardial infarction | Q69894008 |
| | Platelet counts in myocardial infarction, angina pectoris and peripheral artery disease | Q70066992 |
| | The clinical significance of in vitro platelet aggregometry | Q70252681 |
| | Histamine uptake by human platelets | Q70366295 |
| | Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease | Q70405001 |
| | The role of anticoagulation in the measurement of platelet volumes | Q70443729 |
| | A comparison of methods for the study of platelet hyperfunction in thromboembolic disorders | Q70533599 |
| | Platelet function in acute myocardial infarction treated with direct angioplasty | Q70866651 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 177-90 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Clinical and Applied Thrombosis-Hemostasis | Q5133805 |
| P1476 | title | Platelets as predictors of vascular risk: is there a practical index of platelet activity? | |
| | Platelets as Predictors of Vascular Risk: Is There a Practical Index of Platelet Activity? | |
| P478 | volume | 9 | |